~~<i id='2275FD2186'><strike id='2275FD2186'><tt id='2275FD2186'><pre id='2275FD2186'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：focus 2025-09-29 18:03:22 Page View：68229

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Artificial intelligence advances fuel industry trying to preserve loved ones after death
Next article： Activists slam private health insurers over coverage restrictions

knowledge

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

Our daughter's deadly disease: trisomy 18. We wanted to protect her

MariaFabrizioforSTAT“Issheinpain?”Iaskedquietlyasthepearlescentbaby-shapedimageonthescreenfoldeditsl

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Caitlin Bernard's story shows physicians can't shy from advocacy

JustdaysaftertheendofRoev.Wade,CaitlinBernard,anOB-GYNinIndiana,toldtheIndianapolisStaraheartbreakin